Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway

Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway
复制标题

敲除 linc-OIP5 通过下调 YAP-NOTCH 信号通路抑制胶质瘤细胞的增殖和迁移

DOI:
10.1016/j.gene.2017.02.006
复制
发表时间:
2017-04-30
期刊:
影响因子:
3.5
通讯作者:
Lang, Hai-li
Lang, Hai-li
中科院分区:
生物学3区
文献类型:
--
作者:
Hu, Guo-wen;Wu, Lei;Lang, Hai-li

文献摘要

被引文献

相似文献

长基因间非编码RNA(longintergenicnoncodingRNA,lincRNA)在调节胶质瘤生物学功能和分子机制中起重要作用。本研究旨在探讨linc-OIP 5在胶质瘤中的表达水平及其生物学功能。在本研究中,我们使用定量实时聚合酶链反应(qRT-PCR)来确定linc-OIP 5在胶质瘤组织和邻近正常组织中的表达。linc-OIP 5在胶质瘤组织中表达上调,且与肿瘤的晚期(III/IV)显著相关。随后,我们在体外评估了linc-OIP 5-小干扰RNA(siRNA)敲低linc-OIP 5的功效,发现linc-OIP 5敲低可以抑制胶质瘤细胞的体外增殖、迁移和体内肿瘤形成。进一步的机制研究揭示了linc-OIP 5敲低对胶质瘤细胞表型的影响,至少部分地通过下调雅普和抑制Notch信号通路活性。因此,我们的研究提供了证据,linc-OIP 5是一个潜在的治疗靶点和新的胶质瘤的分子生物标志物。(C)2017由Elsevier B. V.出版
Long intergenic noncoding RNAs (lincRNAs) play important roles in regulating the biological functions and underlying molecular mechanisms of glioma. Here, we investigated the expression level and biological function of linc-OIP5 in glioma. In the current study, we used quantitative real-time polymerase chain reaction (qRT-PCR) to determine the expression of linc-OIP5 in glioma tissues and in adjacent normal tissues. Level of linc-OIP5 was up-regulated in glioma tissues and significantly correlated with the advanced tumor stage (III/IV). Subsequently, the efficacy of knockdown of linc-OIP5 by linc-OIP5-small interfering RNA (siRNA) was evaluated in vitro, and we found that knockdown of linc-OIP5 can inhibit glioma cells proliferation, migration in vitro and tumor formation in vivo. Further mechanistic studies revealed the effect of linc-OIP5 knockdown on glioma cell phenotype at least partially through down-regulation of YAP and inhibition of Notch signaling pathway activity. Thus, our study provides evidence that linc-OIP5 is a potential therapeutic target and novel molecular biomarker for glioma. (C) 2017 Published by Elsevier B.V.